Shares of DexCom DXCM lost almost 3% on Jun 3, probably due to concerns about a rise in competition for its recently approved Stelo as the FDA approved a competing product. The FDA approval for Stelo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results